Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

21,027 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 study.
Aitken ML, Burke W, McDonald G, Shak S, Montgomery AB, Smith A. Aitken ML, et al. Among authors: smith a. JAMA. 1992 Apr 8;267(14):1947-51. JAMA. 1992. PMID: 1548827 Clinical Trial.
Tobramycin dosage recommendation in patients with cystic fibrosis.
Davis RL, Mendelman P, Ramsey B, Smith AL. Davis RL, et al. Among authors: smith al. Infection. 1989 Jan-Feb;17(1):41. doi: 10.1007/BF01643502. Infection. 1989. PMID: 2921090 No abstract available.
A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized Tobramycin Study Group.
Eisenberg J, Pepe M, Williams-Warren J, Vasiliev M, Montgomery AB, Smith AL, Ramsey BW. Eisenberg J, et al. Among authors: smith al. Chest. 1997 Apr;111(4):955-62. doi: 10.1378/chest.111.4.955. Chest. 1997. PMID: 9106575 Clinical Trial.
Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis.
Burns JL, Van Dalfsen JM, Shawar RM, Otto KL, Garber RL, Quan JM, Montgomery AB, Albers GM, Ramsey BW, Smith AL. Burns JL, et al. Among authors: smith al. J Infect Dis. 1999 May;179(5):1190-6. doi: 10.1086/314727. J Infect Dis. 1999. PMID: 10191222 Clinical Trial.
Mechanism of amikacin resistance in Pseudomonas aeruginosa isolates from patients with cystic fibrosis.
Hurley JC, Miller GH, Smith AL. Hurley JC, et al. Among authors: smith al. Diagn Microbiol Infect Dis. 1995 Aug;22(4):331-6. doi: 10.1016/0732-8893(95)00138-6. Diagn Microbiol Infect Dis. 1995. PMID: 8582138
Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis.
Smith AL, Redding G, Doershuk C, Goldmann D, Gore E, Hilman B, Marks M, Moss R, Ramsey B, Rubio T, et al. Smith AL, et al. J Pediatr. 1988 Apr;112(4):547-54. doi: 10.1016/s0022-3476(88)80165-3. J Pediatr. 1988. PMID: 3127569
Pharmacokinetics of ticarcillin in patients with cystic fibrosis: a controlled prospective study.
de Groot R, Hack BD, Weber A, Chaffin D, Ramsey B, Smith AL. de Groot R, et al. Among authors: smith al. Clin Pharmacol Ther. 1990 Jan;47(1):73-8. doi: 10.1038/clpt.1990.11. Clin Pharmacol Ther. 1990. PMID: 2295222
Disposition of drugs in cystic fibrosis. II. Hepatic blood flow.
O'Sullivan TA, Bauer LA, Horn JR, Zierler BK, Strandness DE Jr, Williams-Warren J, Smith AL, Unadkat JD. O'Sullivan TA, et al. Among authors: smith al. Clin Pharmacol Ther. 1991 Oct;50(4):450-5. doi: 10.1038/clpt.1991.163. Clin Pharmacol Ther. 1991. PMID: 1914381
Disposition of drugs in cystic fibrosis. III. Acetaminophen.
Hutabarat RM, Unadkat JD, Kushmerick P, Aitken ML, Slattery JT, Smith AL. Hutabarat RM, et al. Among authors: smith al. Clin Pharmacol Ther. 1991 Dec;50(6):695-701. doi: 10.1038/clpt.1991.209. Clin Pharmacol Ther. 1991. PMID: 1752114
Predictive value of oropharyngeal cultures for identifying lower airway bacteria in cystic fibrosis patients.
Ramsey BW, Wentz KR, Smith AL, Richardson M, Williams-Warren J, Hedges DL, Gibson R, Redding GJ, Lent K, Harris K. Ramsey BW, et al. Among authors: smith al. Am Rev Respir Dis. 1991 Aug;144(2):331-7. doi: 10.1164/ajrccm/144.2.331. Am Rev Respir Dis. 1991. PMID: 1859056
21,027 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback